Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant
Status: | Terminated |
---|---|
Conditions: | Gastrointestinal |
Therapuetic Areas: | Gastroenterology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 1/6/2018 |
Start Date: | June 30, 2017 |
End Date: | December 31, 2017 |
A Two-Part, Open-Label, Single-Dose Study to Investigate the Influence of Hepatic Insufficiency on the Pharmacokinetics of Tozadenant
This is a two-part, open label, single-dose study that will evaluate the PK of tozadenant in
subjects with different degrees of hepatic impairment to the PK of a single-dose of
tozadenant in healthy subjects.
subjects with different degrees of hepatic impairment to the PK of a single-dose of
tozadenant in healthy subjects.
Inclusion Criteria:
All subjects must fulfill the following to participate:
- Subject has given his/her written informed consent on an IEC or IRB approved consent
form.
- Subject understands the study procedures in the informed consent form (ICF), and is
willing and able to comply with the protocol.
- Be either male or female 18 years old
- Have a BMI ≥ 18.5 and ≤ 40.0 kg/m2 at screening
- Is a continuous non-smoker or a smoker who will consume up to 10 cigarettes/day
- Child bearing females should be sexually inactive (abstinent) prior to dosing
- Females subjects of non childbearing potential must have undergone one of the
following sterilization or be postmenopausal
Subjects with mild, moderate, or severe hepatic impairment must:
- Have a medical history consistent with a diagnosis of hepatic impairment.
- Have a diagnosis of chronic (> 6 months), stable hepatic insufficiency
Healthy subjects must be:
- Medically healthy with no significant medical history
Exclusion Criteria:
Subjects must not be enrolled in the study if they:
- Previously participated in any study with tozadenant
- Has orthostatic hypotension, history or symptoms of cardiovascular disease, or
hypertensive crisis.
- Currently participating in or has participated in another study and received drug
(active or placebo)
- Have a known diagnosis of malignant melanoma
- Have a current episode of major depression
- Has a recent history of suicide attempt
- Has any other condition or clinically significant abnormal findings on the physical or
neurological examination, psychiatric and medical history
- Had surgery or any medical condition within 6 months
- Unable to refrain from or anticipates the use of any drugs, vitamins, natural or
herbal supplements
- Subject is currently lactating or pregnant or planning to become pregnant.
- Recent donation of blood, plasma or significant blood loss
- Has positive test for ethanol or drugs of abuse or a history of chronic alcohol or
drug abuse
- Clinically significant medical history
- Positive results hepatitis B surface antigen (HBsAg) or hepatitis C virus (HCV) for
Healthy Volunteers only.
We found this trial at
2
sites
University of Miami A private research university with more than 15,000 students from around the...
Click here to add this to my saved trials
5055 South Orange Ave Orlando FL 32909
Orlando, Florida 32806
Orlando, Florida 32806
407-240-7878
Click here to add this to my saved trials